National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 53 of 66
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
NCT00047307
Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
NCT00045188
Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer
NCT00045331
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
NCT00052559
E7389 in Treating Patients With Advanced Solid Tumors
NCT00047034
Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
NCT00047333
Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00049088
Collection of Blood, Bone Marrow, Tumor or Tissue Samples
NCT00043615
HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)
NCT00339430
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCT00040222
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
NCT00025155
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
NCT00055861
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00046917
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
NCT00042991
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
NCT00004856
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
NCT00039624
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
NCT00005845
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
NCT00031915
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00027690
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00017264
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
NCT00045500
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
NCT00045526
Gefitinib in Treating Children With Refractory Solid Tumors
NCT00040781
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00041041
Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
NCT00040365
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery
NCT00043121
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
NCT00041197
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)
NCT00045396
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
NCT00036855
Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
NCT00042952
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
NCT00037817
Influence of Corn Farming on the Immune System
NCT00342121
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
NCT00039182
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
NCT00030667
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00040755
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
NCT00041106
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NCT00039611
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00042809
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00042874
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
NCT00039585
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00040794
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
NCT00036569
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00045097
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
NCT00041340
EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer
NCT02154399
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
NCT00042835
Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols
NCT00035373
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
NCT00340548
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT00025233
Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain
NCT00032097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.